Single dose treatment with Tiberal of Giardia lamblia infection in children

Giardiasis: a pharmacotherapy review

Giardia lamblia, the cause of human giardiasis, is among the most common intestinal protozoa worldwide. Human infection may range from asymptomatic shedding of giardial cysts to symptomatic giardiasis, being responsible for abdominal cramps, nausea, acute or chronic diarrhoea, with malabsorption and failure of children to thrive. At present, treatment options include the nitroimidazoles derivatives; especially metronidazole, which has been the mainstay of treatment for decades and is still widely used. The increasing number of reports of refractory cases with this group of drugs and other antigiardial agents, has raised concern and led to a search for other compounds, some of which have arisen due to the introduction of drugs initially addressed to other diseases. The present article examines some of the most important points of antigiardial pharmacotherapy available at present and the future prospects of development of new agents.

Efficacy of antigiardial drugs

The flagellated protozoa Giardia duodenalis is the most commonly detected parasite in the intestinal tract of humans. Infections with the parasite result in diarrhoeal disease in humans and animals, with infants at risk from failure-to-thrive syndrome. The incidence of giardiasis worldwide may be as high as 1000 million cases. Current recommended treatments include the nitroheterocyclic drugs tinidazole, metronidazole and furazolidone, the substituted acridine, quinacrine, and the benzimidazole, albendazole. Paromomycin is also used in some situations, and nitazoxanide is proving to be useful. However, treatment failures have been reported with all of the common antigiardial agents, and drug resistance to all available drugs has been demonstrated in the laboratory. In addition, clinical resistance has been reported, including cases where patients failed both metronidazole and albendazole treatments. The identification of new antigiardial drugs is an important consideration for the future, but maintaining the usefulness of the existing drugs is the most cost-effective measure to ensure the continued availability of antigiardial drugs.

Single-dose ornidazole versus seven-day metronidazole therapy of giardiasis in Kibbutzim children in Israel

The efficacy of single-dose ornidazole versus seven days metronidazole in the treatment of giardiasis was tested in a randomized study of 75 Kibbutzim children in Israel. All the children treated were clinically cured, and the parasites disappeared from stool examinations after the first follow-up. By the end of the study (21 days after the beginning of treatment), all the patients remained free of symptoms, but cysts of Giardia lamblia were found in the stools of three children from the ornidazole group (p = 0.24). The possibility of treating Giardia lamblia with ornidazole in a single dose, with results similar to those obtained with a seven-day course of metronidazole, makes this drug a good alternative in the treatment of Giardia lamblia in children, especially if compliance is not assured.

Parasitic diseases of the small intestinal tract

The epidemiology, clinical aspects, and treatment of human intestinal infections with Giardia, Cryptosporidium, coccidia and Strongyloides in industrialized countries are reviewed. In well-nourished and immunocompetent persons, inapparent infections or mild, transitory gastrointestinal upsets caused by these parasites are quite common. Some patients develop severe symptoms, such as profuse diarrhoea, dehydration, stool irregularities for weeks or months followed by weight loss and malabsorption of fat, vitamins and iron. In patients receiving immunosuppressive treatment or with lymphotropic viral infections, Cryptosporidium and Strongyloides can cause life-threatening or debilitating disease. By autoinfection or external reinfection these parasites can persist in the intestine for years. Clinicians should consider such infections in immigrants, travellers and former servicemen, even long after their stay in endemic areas, and also in the handicapped and children in day-care centres.